Express News | Incyte To Present Late-Breaking Tafasitamab Data In Follicular Lymphoma At ASH 2024 Alongside 20 Oncology Portfolio Updates, Including Phase 3 InMIND Results And Virtual Analyst Event On December 12

BenzingaNov 25 10:10 ET

S&P 500, Dow Hit Records Right After Open | Live Stock

Kevin TraversNov 25 10:00 ET

TD Cowen Maintains Incyte(INCY.US) With Buy Rating, Raises Target Price to $86

Moomoo NewsNov 25 08:32 ET · Ratings

TD Cowen Remains a Buy on Incyte (INCY)

TipRanksNov 25 07:47 ET · Ratings

TD Cowen Adjusts Price Target on Incyte to $86 From $80, Keeps Buy Rating

MT NewswiresNov 25 06:47 ET · Ratings

Weekly Buzz: Nvidia Falls on Near Perfect Report, but Only For a Day

Kevin TraversNov 22 16:17 ET